Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in Decembe
IPO Year: 2012
Exchange: NYSE
Website: htgc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/16/2024 | $17.00 → $17.50 | Buy → Neutral | Compass Point |
| 11/21/2023 | $17.00 | Neutral | UBS |
| 8/30/2023 | $17.50 | Neutral → Buy | Compass Point |
| 8/4/2023 | $13.50 → $17.00 | Underperform → Mkt Perform | Keefe Bruyette |
| 4/6/2023 | $16.00 | Neutral → Overweight | Piper Sandler |
| 3/13/2023 | $14.50 → $10.50 | Mkt Perform → Underperform | Keefe Bruyette |
| 7/29/2022 | Outperform → Perform | Oppenheimer | |
| 4/22/2022 | $18.00 | Outperform → Mkt Perform | Keefe Bruyette |
| 4/4/2022 | $19.00 | Overweight → Neutral | Piper Sandler |
| 2/8/2022 | $18.00 | Buy → Neutral | Compass Point |
8-K - Hercules Capital, Inc. (0001280784) (Filer)
10-Q - Hercules Capital, Inc. (0001280784) (Filer)
424B3 - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
10-Q - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
144 - Hercules Capital, Inc. (0001280784) (Subject)
8-K - Hercules Capital, Inc. (0001280784) (Filer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE:HTGC) for up to $50 million. "Alector is in a strong cash position with more than $457 million in cash and investments. This credit facility further enhances our financial strength and provides the Company with increased strategic and operational flexibility," said Marc Grasso, M.D., Chief Financial Officer of Alector. "We anticipate transformational data from both the AL002 INVOKE-2 Phase 2 trial and the latozinemab INFRO
Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80 million available at Disc's sole discretion through second-half 2026Funding can support development across the portfolio, including the recently announced potential accelerated approval pathway for bitopertin in EPP WATERTOWN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it has obtained a $200 million non-dilut
Behavox, a leading provider of AI-driven compliance solutions for Financial Services, announced today that it has secured a $70 million credit facility from Hercules Capital, Inc. (NYSE:HTGC), further increasing ample liquidity reserves on its balance sheet. Behavox intends to use the funds for strategic acquisitions and the building of new products to deliver more value to compliance teams globally. Today, Behavox is recognized as the leading provider of communication surveillance and regulatory archiving solutions. In response to the strong market demand, Behavox plans to expand its product portfolio in 2025, adding new solutions for Trade Surveillance, Control Room, and Sanction Screeni
Record Q3 2024 Total Investment Income of $125.2 Million, an Increase of 7.3% Year-over-Year Q3 2024 Net Investment Income "NII" of $83.2 Million, or $0.51 per Share, an Increase of 8.3% Year-over-Year Q3 2024 NII Provides 128% Coverage of the Base Cash Distribution Q3 2024 Total Gross Debt and Equity Commitments of $430.7 Million Q3 2024 Total Gross Fundings of $272.0 Million Conservative Balance Sheet Management with Net GAAP Leverage of 92.5% and Net Regulatory Leverage of 83.0% Undistributed Earnings Spillover of $152.1 Million, or $0.94(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an Increase of 10.9% Year-over-Year(2) Hercules Capital
The Total Cash Distribution of $0.48 per Share for the Third Quarter 2024 is Comprised of a $0.40 per Share Base Distribution and an $0.08 per Share Supplemental Distribution Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a third quarter 2024 total cash distribution of $0.48 per share. The following shows the key dates of the third quarter 2024 distribution payment: Record Date November 13, 202
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its third quarter 2024 financial results conference call for Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Moody's Investors Service, Inc. ("Moody's") has reaffirmed Hercules an investment grade credit and corporate rating of Baa3 with a revised outlook to positive, as well as its underlying analysis. "We are very pleased that Moody's has reaffirmed our Baa3 investment grade credit rating and revised our outlook to positive from stable," stated Seth Meyer, chief financial officer of Hercules. "This rating
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that members of the executive management team will be participating at the following event for the financial community: KBW 2024 BDC Midtown March New York, NY Wednesday, October 2, 2024 Participation and/or meetings with management can be arranged with KBW. About Hercules Capital, Inc. Hercules Capital, Inc. (NYSE:HTGC) is the leading and largest specialty finance company focused on providing senior se
Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. $150 million committed, of which $50 million was drawn at closing and the remaining $100 million available at Arcus's sole discretion. Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported it has obtained a $250 million term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in life sciences and technology-related markets. The additional capital strengthens Arcus's
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Kroll Bond Rating Agency, Inc. ("KBRA") has reaffirmed Hercules' investment grade corporate and credit rating of BBB+. KBRA issued a statement announcing the reaffirmation of the rating and stable outlook, as well as its underlying analysis. "We are very pleased that KBRA has reaffirmed our BBB+ investment grade corporate and credit rating," stated Seth Meyer, chief financial officer of Hercules. "Th
Record Q3 2024 Total Investment Income of $125.2 Million, an Increase of 7.3% Year-over-Year Q3 2024 Net Investment Income "NII" of $83.2 Million, or $0.51 per Share, an Increase of 8.3% Year-over-Year Q3 2024 NII Provides 128% Coverage of the Base Cash Distribution Q3 2024 Total Gross Debt and Equity Commitments of $430.7 Million Q3 2024 Total Gross Fundings of $272.0 Million Conservative Balance Sheet Management with Net GAAP Leverage of 92.5% and Net Regulatory Leverage of 83.0% Undistributed Earnings Spillover of $152.1 Million, or $0.94(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an Increase of 10.9% Year-over-Year(2) Hercules Capital
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its third quarter 2024 financial results conference call for Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access
Q2 2024 Total Gross Debt and Equity Commitments of $686.5 Million Record Q2 2024 Total Gross Fundings of $461.5 Million, an Increase of 28.7% Year-over-Year Record Q2 2024 Total Investment Income of $125.0 Million, an Increase of 7.5% Year-over-Year Q2 2024 Net Investment Income "NII" of $82.4 Million, or $0.51 per Share, an Increase of 8.8% Year-over-Year Q2 2024 NII Provides 128% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net GAAP Leverage of 93.3% and Net Regulatory Leverage of 83.9% Undistributed Earnings Spillover of $145.0 Million, or $0.89(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an In
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2024 financial results conference call for Thursday, August 1, 2024, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2024 Annual Meeting of Stockholders by virtual meeting on Thursday, June 20, 2024 at 9:00 a.m. (Pacific Time). The proxy statement for the meeting was filed on April 23, 2024 and mailed to stockholders of record as of April 19, 2024. 2024 Annual Meeting of Stockholders June 20, 2024 at 9:00 a.m. Pacific Time Virtual Meeting via Internet: www.virtualshareholdermeeting.com/HTGC2024 Matters to be voted on include: 1) election of three independent directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common
Record Q1 2024 Total Gross Debt and Equity Commitments of $956.0 Million, an Increase of 81.7% Year-over-Year Record Q1 2024 Total Gross Fundings of $605.2 Million, an Increase of 27.1% Year-over-Year Q1 2024 Total Investment Income of $121.6 Million, an Increase of 15.7% Year-over-Year Q1 2024 Net Investment Income "NII" of $79.2 Million, or $0.50 per Share, an Increase of 20.9% Year-over-Year Q1 2024 NII Provides 125% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net GAAP Leverage of 91.0% and Net Regulatory Leverage of 81.7% Undistributed Earnings Spillover of $142.7 Million, or $0.88(1) per Ending Shares Outstanding Approximately $4.5 Bi
Two Decades of Fueling the Growth of the Innovation Economy Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), is celebrating its 20th year of originations activity by reaching the $20.0 billion milestone in total debt commitments. Founded in December 2003, and originating its first deal in 2004, the Company's mission was simple: Provide entrepreneurs with an alternative source of growth capital that complements a growth stage company's existing institutional financing. Today, Hercules Capital is the largest and leading specialty financing provider to innovative venture, growth and established stage companies, having partnered with over 650 technology and life sciences po
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its first quarter 2024 financial results conference call for Thursday, May 2, 2024, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the
Record Q4 2023 Total Investment Income of $122.6 Million, an Increase of 22.4% Year-over-Year Record Q4 2023 Net Investment Income "NII" of $86.0 Million, or $0.56 per Share, an Increase of 38.5% Year-over-Year Record Full-Year 2023 Total Investment Income of $460.7 Million, an Increase of 43.2% Year-over-Year Record Full-Year 2023 Net Investment Income "NII" of $304.0 Million, an Increase of 61.7% Year-over-Year Record Full-Year 2023 Total Gross Fundings of $1.6 billion, an Increase of 9.1% Year-over Year Inclusive of the Adviser Funds Managed by Hercules Adviser LLC, its Wholly-owned Subsidiary, Hercules had over $1.0 Billion of Available Liquidity as of Year End Q4 2023 NII P
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2023 financial results conference call for Thursday, February 15, 2024, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can b
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
4 - Hercules Capital, Inc. (0001280784) (Issuer)
SC 13G - Hercules Capital, Inc. (0001280784) (Subject)
SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)
SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)
5 analysts have expressed a variety of opinions on Hercules Capital (NYSE:HTGC) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 3 1 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.5, a high estimate of $22.00, and a low estimate of $19.00. Observing a 3.54% increase, the current average has
Piper Sandler analyst Crispin Love maintains Hercules Capital (NYSE:HTGC) with a Overweight and raises the price target from $21.5 to $22.
On CNBC's “Halftime Report Final Trades,” Stephen Weiss of Short Hills Capital Partners said Alphabet Inc. (NASDAQ:GOOG) (NASDAQ:GOOGL) has been on a roll and will continue to be. The company had a great developers conference and made great announcements, he said. Google last week announced a new feature that will use artificial intelligence to detect theft and lock the screen of Android smartphones. Kevin Simpson of Capital Wealth Planning said Honeywell International Inc. (NASDAQ:HON) has increasing cash flow and margins. He expects analysts to increase estimates and price targets for the stock. On April 25, Honeywell International reported first-quarter fiscal 2024 sales of $9.1
JMP Securities analyst Devin Ryan maintains Hercules Capital (NYSE:HTGC) with a Market Outperform and raises the price target from $19 to $20.
Wells Fargo analyst Finian O'Shea maintains Hercules Capital (NYSE:HTGC) with a Overweight and raises the price target from $19.5 to $20.
Piper Sandler analyst Crispin Love maintains Hercules Capital (NYSE:HTGC) with a Overweight and raises the price target from $21 to $21.5.
Keefe, Bruyette & Woods analyst Paul Johnson maintains Hercules Capital (NYSE:HTGC) with a Market Perform and raises the price target from $18 to $19.
Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously
UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00
Compass Point upgraded Hercules Capital from Neutral to Buy and set a new price target of $17.50
Keefe Bruyette upgraded Hercules Capital from Underperform to Mkt Perform and set a new price target of $17.00 from $13.50 previously
Piper Sandler upgraded Hercules Capital from Neutral to Overweight and set a new price target of $16.00
Keefe Bruyette downgraded Hercules Capital from Mkt Perform to Underperform and set a new price target of $10.50 from $14.50 previously
Oppenheimer downgraded Hercules Capital from Outperform to Perform
Keefe Bruyette downgraded Hercules Capital from Outperform to Mkt Perform and set a new price target of $18.00
Piper Sandler downgraded Hercules Capital from Overweight to Neutral and set a new price target of $19.00
Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $18.00
SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Pam Randhawa was appointed to serve as a member of its board of directors, effective November 1, 2021. Ms. Randhawa is a thought leader within the life sciences sector and an experienced industry executive, with more than 20 years of experience leading public and private companies, ranging from biotech, healthcare and sustainable solutions, through their various stages of growth. Ms. Randhawa will ser
Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that effective July 1, 2021, Wade Loo was appointed to the Hercules board of directors. Mr. Loo brings over 40 years of business experience in all aspects of financial reporting serving public companies – from emerging startups going public to large-cap multinationals. Mr. Loo will serve on the Audit Committee. "Wade provides relevant financial business expertise that complements our leading venture lendi